#USA #Minneapolis #VentureMed Group #FLEX Vessel Prep #angioplasty

Revolutionary Insights from Charing Cross Symposium

Recent advancements in medical technology were highlighted at the Charing Cross Symposium held from April 23 to 25, 2025, in London, showcasing groundbreaking data about the FLEX Vessel Prep™ System by VentureMed Group, Inc. This private company specializes in innovations aimed at improving arteriovenous (AV) access and peripheral arterial disease (PAD) treatments.

The presentations centered around two significant studies that provided compelling evidence supporting the effectiveness and safety of the FLEX Vessel Prep System. The system is engineered to enhance vessel preparation, crucial for maximizing procedural outcomes while minimizing complications during angioplasty.

Presentation Highlights

1. FLEX FIRST AV Registry: Six-Month Outcomes

Leading the discussion was Dr. Ari Kramer from Spartanburg Medical Center, who presented data from the FLEX FIRST AV Registry. This multicenter observational study engaged 130 hemodialysis patients facing vascular access dysfunction. The findings revealed impressive results, showcasing the safety and durability of the FLEX procedure in challenging patient populations.

Key takeaways included:

• - 0 serious adverse events reported within one month post-procedure.
• - A remarkable 70.7% primary lesion target patency rate at six months.
• - An impressive 76.3% patency rate specifically within cephalic arch lesions, highlighting the method's effectiveness.
• - 100% technical success in delivering devices across all procedures, underscoring the reliability of the FLEX Vessel Prep System.

Dr. Kramer emphasized, "The FLEX VP System fundamentally changed my approach to dealing with resistant stenoses, and these outcomes validate the clinical advantages we’ve observed firsthand." His perspective portrays FLEX as not merely a tool, but as a paradigm shift in vascular preparation techniques, leading to a more refined, surgical-like methodology in endovascular precision medicine.

2. Comparative Effects of Vessel Preparation Before Drug-Eluting Angioplasty

In a further presentation, Dr. Robert Shahverdyan spoke on the proactive role of vessel preparation before drug-eluting angioplasty. An analysis of over 70 patients indicated a substantial reduction in reintervention rates when using the FLEX system compared to traditional high-pressure and ultra-high-pressure balloon methods.

Findings included:

• - A primary target lesion patency rate of 86.0% at six months and 73.6% at 12 months for the FLEX + drug-coated balloon (DCB) combination. This significantly surpasses patency rates established with other conventional methods.
• - The average number of reinterventions annually was markedly lower in the FLEX group (0.372) than in POBA (0.695) and SB (0.917) groups (p<0.0001).
• - Encouragingly, three out of four interventions in the cephalic arch maintained target lesion patency at 12 months using the FLEX + DCB, indicating enhanced long-term outcomes.

Dr. Shahverdyan expressed optimism about the FLEX approach, stating, "Flexibility in our methods for resistant stenoses positions FLEX as my preferred vessel preparation technique, transforming access maintenance strategies for our patients."

Why Choose FLEX for Vessel Preparation?

VentureMed Group’s CEO Denis Harrington voiced his gratitude towards the contributions of both Dr. Kramer and Dr. Shahverdyan, commending their diligent work. He noted, "These findings contribute significantly to the success evidence base of the FLEX Vessel Prep system, ensuring that AV Access patients globally have the required access to validated technologies that these studies represent."

About VentureMed Group Inc.

VentureMed Group is at the forefront of medical device technology, dedicated to advancing endovascular solutions for AV access and procedures related to PAD. Their flagship technology, the FLEX Vessel Prep™ System, leverages proprietary Kinetic Endovascular Micro-incision Creation (KEMIC) to optimize vessel preparation. This innovative technique is designed to create controlled, precise micro-incisions, improving patency rates while minimizing tissue trauma and the risk of restenosis. With FDA 510(k) clearance and CE Mark approval, FLEX is redefining how vascular preparation is approached and enhancing therapeutic options for patients worldwide.

For further details, you can visit VentureMed Group's website.